Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • br We sincerely appreciate the comment by

    2019-04-26


    We sincerely appreciate the comment by Lombardi et al on our published paper. demonstrates the incidence of dyspnea and the discontinuation of ticagrelor due to dyspnea in patients who reported dyspnea in Phase 3/4 clinical trials of acute coronary syndrome with available relevant data. Our study revealed that UNC1999 the incidence of dyspnea-related discontinuation of PY antagonist treatment in patients UNC1999 with dyspnea tended to be higher in the ticagrelor group (17.0%), which was similar to previous real-world studies. When compared with clopidogrel treatment, ticagrelor causes a first law of thermodynamics (conservation) fourfold increase in the incidence of dyspnea requiring discontinuation of a PY antagonist, according to our study; the result was very similar to that of the Study of Platelet Inhibition and Patient Outcomes trial (a 3.4-fold increase). In light of the advantages and disadvantages of randomized controlled trials and observational studies, both clinical and observational evidence should not be mutually exclusive and should actually be complementary. Conflicts of interest